FFJ short Intra-Cellular, says users reporting ‘particularly toxic side effect’

In a recently published report, The Foundation for Financial Journalism says that, "Intra-Cellular Therapies holds itself out to both patients and investors as a fast-growing, lab coats-to-riches story… But the truth of Caplyta – and perhaps even the drug’s future – may be much cloudier than Intra-Cellular is letting on. That’s because Caplyta’s users are making themselves heard across the internet regarding their experiences with a particularly toxic side effect… And many of them have a lot to say about a specific Caplyta side effect whereby they become uncomfortably hot after taking their first dose." According to FFJ, "Where this side effect is most visible is in the FDA’s own adverse events reporting system, or FAERS." Reference Link